LEADER 04439nam 22006493 450 001 9910508303503321 005 20211110210524.0 010 $a1-84545-866-4 010 $a9786612627330 010 $a1-282-62733-3 035 $a(MiAaPQ)EBC544297 035 $a(Au-PeEL)EBL544297 035 $a(CaPaEBR)ebr10394271 035 $a(CaONFJC)MIL262733 035 $a(OCoLC)645100592 035 $a(PZ_Ebook Central)EBC544297 035 $a(CKB)19356306800041 035 $a(EXLCZ)9919356306800041 100 $a20211110d2008 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aGerman Literature in a New Century $eTrends, Traditions, Transitions, Transformations 205 $a1st ed. 210 1$aNew York, NY :$cBerghahn Books, Incorporated,$d2008. 210 4$dİ2008. 215 $a1 online resource (310 pages) 311 08$aPrint version: Gerstenberger, Katharina German Literature in a New Century New York, NY : Berghahn Books, Incorporated,c2008 9780857451682 327 $aTitle page-German Literature in a New Century -- Contents -- Acknowledgements -- Introduction -- Part I-Trends -- Chapter 1-The litarary public sphere -- Chapter 2-Intellectuals in the public sphere -- Chapter 3-'Literatur Findet...Nicht Nur Auf Papier Statt -- Chapter 4-The Deutsches Literaturinstitut Leipzig and the Making of an Author -- Part II-Traditions -- Chapter 5-Degrees of History in Contemporary German Narratives -- Chapter 6-Luftkrieg Revisited -- Chapter 7-An Aesthetics of Memory for third-generation Germans -- Chapter 8-The continuation of countermemory -- Part III-Transitions -- Chapter 9-A Path of Poetic Potentials -- Chapter 10-Performing GDR in Poetry? -- Chapter 11-Feridum Zaimoglu's Performance of Gender and Authorship -- Part IV-Transformations -- Chapter 12-From Frauenliteratur to Frauenliteraturbetrieb -- Chapter 13-Social Alienation and Gendered Surveillance -- Chapter 14-Small Stories -- Chapter 15-The young author as public intellectual -- Contributors -- Index. 330 $aWhile the first decade after the fall of the Berlin wall was marked by the challenges of unification and the often difficult process of reconciling East and West German experiences, many Germans expected that the "new century" would achieve "normalization." The essays in this volume take a closer look at Germany's new normalcy and argue for a more nuanced picture that considers the ruptures as well as the continuities. Germany's new generation of writers is more diverse than ever before, and their texts often not only speak of a Germany that is multicultural but also take a more playful attitude toward notions of identity. Written with an eye toward similar and dissimilar developments and traditions on both sides of the Atlantic, this volume balances overviews of significant trends in present-day cultural life with illustrative analyses of individual writers and texts. 606 $aGerman literature -- 20th century -- History and criticism 606 $aGerman literature -- 21st century -- History and criticism 606 $aGerman literature -- Europe, German-speaking -- History and criticism 606 $aGerman literature -- Appreciation -- Europe, German-speaking 606 $aEurope, German-speaking -- Intellectual life -- 20th century 606 $aEurope, German-speaking -- Intellectual life -- 21st century 606 $aUnited States -- Intellectual life -- 20th century 608 $aElectronic books. 615 0$aGerman literature -- 20th century -- History and criticism. 615 0$aGerman literature -- 21st century -- History and criticism. 615 0$aGerman literature -- Europe, German-speaking -- History and criticism. 615 0$aGerman literature -- Appreciation -- Europe, German-speaking. 615 0$aEurope, German-speaking -- Intellectual life -- 20th century. 615 0$aEurope, German-speaking -- Intellectual life -- 21st century. 615 0$aUnited States -- Intellectual life -- 20th century. 676 $a830.90092 700 $aGerstenberger$b Katharina$01024945 701 $aHerminghouse$b Patricia$01024946 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910508303503321 996 $aGerman Literature in a New Century$92436432 997 $aUNINA LEADER 01344nam a2200397 i 4500 001 991001165109707536 005 20020507184435.0 008 950503s1972 us ||| | eng 020 $a0691081204 035 $ab10809776-39ule_inst 035 $aLE01308062$9ExL 040 $aDip.to Matematica$beng 082 0 $a515.353 084 $aAMS 35F15 084 $aAMS 35H05 084 $aAMS 35N15 084 $aAMS 58G05 084 $aQA374 100 1 $aFolland, Gerald B.$041512 245 14$aThe Neumann problem for the Cauchy-Riemann complex /$cby G. B. Folland and J. J. Kohn 260 $aPrinceton, N.J., :$bPrinceton Univ. Press,$c1972 300 $aviii, 146 p. ;$c24 cm. 490 0 $aAnnals of mathematics studies ;$v75 500 $aBibliography: p. 136-141 650 0$aBoundary value problems 650 0$aComplex manifolds 650 0$aDifferential operators 650 0$aHypoelliptic equations 650 0$aNeumann problem 700 1 $aKohn, Joseph John 907 $a.b10809776$b23-02-17$c28-06-02 912 $a991001165109707536 945 $aLE013 35N FOL11 (1972)$g1$i2013000028002$lle013$o-$pE0.00$q-$rl$s- $t0$u4$v6$w4$x0$y.i10915011$z28-06-02 996 $aNeumann problem for the Cauchy-Riemann complex$9924986 997 $aUNISALENTO 998 $ale013$b01-01-95$cm$da $e-$feng$gus $h4$i1 LEADER 06995nam 22013213u 450 001 9910808713803321 005 20251116164038.0 010 $a1-283-20363-4 010 $a9786613203632 010 $a0-470-92935-9 010 $a0-470-92934-0 035 $a(CKB)2550000000042753 035 $a(EBL)818637 035 $a(OCoLC)746598445 035 $a(SSID)ssj0000534041 035 $a(PQKBManifestationID)12165841 035 $a(PQKBTitleCode)TC0000534041 035 $a(PQKBWorkID)10493413 035 $a(PQKB)10894419 035 $a(MiAaPQ)EBC818637 035 $a(PPN)190360267 035 $a(EXLCZ)992550000000042753 100 $a20131230d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiviral Drugs $eFrom Basic Discovery Through Clinical Trials 205 $a1st ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (470 p.) 300 $aDescription based upon print version of record. 311 08$a1-118-25122-9 311 08$a0-470-45563-2 327 $aANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 327 $a7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 327 $a14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 327 $a21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 327 $a29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate 330 $aThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so 606 $aAntiviral Agents -- therapeutic use 606 $aAntiviral agents 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aDrug Evaluation 606 $aAntiviral agents 606 $aEpidemiologic Studies 606 $aChemistry, Pharmaceutical 606 $aEvaluation Studies as Topic 606 $aInvestigative Techniques 606 $aAnti-Infective Agents 606 $aEpidemiologic Methods 606 $aPharmacology 606 $aTherapeutic Uses 606 $aHealth Care Evaluation Mechanisms 606 $aChemistry 606 $aBiological Science Disciplines 606 $aNatural Science Disciplines 606 $aQuality of Health Care 606 $aPublic Health 606 $aPharmacologic Actions 606 $aEnvironment and Public Health 606 $aHealth Care Quality, Access, and Evaluation 606 $aChemical Actions and Uses 606 $aDelivery of Health Care 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aAntiviral Agents 606 $aDrug Evaluation 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAntiviral Agents -- therapeutic use. 615 4$aAntiviral agents. 615 4$aClinical Trials as Topic. 615 4$aDrug Discovery. 615 4$aDrug Evaluation. 615 0$aAntiviral agents. 615 2$aEpidemiologic Studies. 615 2$aChemistry, Pharmaceutical. 615 2$aEvaluation Studies as Topic. 615 2$aInvestigative Techniques. 615 2$aAnti-Infective Agents. 615 2$aEpidemiologic Methods. 615 2$aPharmacology. 615 2$aTherapeutic Uses. 615 2$aHealth Care Evaluation Mechanisms. 615 2$aChemistry. 615 2$aBiological Science Disciplines. 615 2$aNatural Science Disciplines. 615 2$aQuality of Health Care. 615 2$aPublic Health. 615 2$aPharmacologic Actions. 615 2$aEnvironment and Public Health. 615 2$aHealth Care Quality, Access, and Evaluation. 615 2$aChemical Actions and Uses. 615 2$aDelivery of Health Care. 615 2$aClinical Trials as Topic. 615 2$aDrug Discovery. 615 2$aAntiviral Agents. 615 2$aDrug Evaluation. 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.7924 700 $aKazmierski$b Wieslaw M$01671234 702 $aKazmierski$b Wieslaw M. 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910808713803321 996 $aAntiviral Drugs$94033635 997 $aUNINA